Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

This study is testing a new way of delivering cisplatin — a standard chemotherapy drug — by inhaling it as a dry powder directly into the lungs, rather than receiving it intravenously (through a vein). This approach aims to deliver the drug more precisely to lung tumors while potentially reducing the systemic side effects that occur when it travels through the whole body. The study includes patients with stage IV non-small cell lung cancer (NSCLC) who would normally receive pembrolizumab-based treatment. **You may be eligible if...** - You are 18 years or older - You have confirmed stage IV NSCLC that is eligible for treatment with pembrolizumab (alone or with carboplatin/pemetrexed or paclitaxel) - You have measurable disease on imaging - You have not previously received systemic treatment for your lung cancer - Your lung function is adequate for inhaled therapy **You may NOT be eligible if...** - You have small cell lung cancer or another non-NSCLC type - You have certain genetic mutations that are targeted by approved therapies (like EGFR or ALK) - You have active or uncontrolled brain metastases - You have significant lung disease (such as severe COPD or interstitial lung disease) that would make inhaled therapy unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.